Cellular, Tissue and Gene Therapies Advisory Committee; Amendment of Notice, 65693 [2012-26635]
Download as PDF
<![CDATA[
65693
Federal Register / Vol. 77, No. 210 / Tuesday, October 30, 2012 / Notices
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
ACF–196T ........................................................................................................
Estimated Total Annual Burden
Hours: 224.
In compliance with the requirements
of Section 506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade SW., Washington, DC 20447,
Attn: ACF Reports Clearance Officer.
Email address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2012–26575 Filed 10–29–12; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
wreier-aviles on DSK7SPTVN1PROD with NOTICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Cellular, Tissue and Gene Therapies
Advisory Committee; Amendment of
Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Mar<15>2010
13:17 Oct 29, 2012
Jkt 229001
56
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of a meeting of the Cellular,
Tissue and Gene Therapies Advisory
Committee. This meeting was
announced in the Federal Register of
October 17, 2012 (77 FR 63840–63841).
The amendment is being made to reflect
a change in the Date and Time, Agenda,
Procedure, and Closed Committee
Deliberations portions of the document.
There are no other changes.
FOR FURTHER INFORMATION CONTACT: Gail
Dapolito or Sheryl Clark, Center for
Biologics Evaluation and Research
(HFM–71), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852, 301–827–0314, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington DC area). Please call
the Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of October 17, 2012,
FDA announced that a meeting of the
Cellular, Tissue and Gene Therapies
Advisory Committee would be held on
November 29, 2012. On page 63841, in
the first column, the Date and Time
portion of the document is changed to
read as follows:
The teleconference meeting will be
held on November 29, 2012 from 1 p.m.
to 4:30 p.m., Eastern Time.
On page 63841, in the first column,
last paragraph, the Agenda portion is
changed to read as follows:
On November 29, 2012 the committee
will meet in open session to hear
updates of research programs in the
Gene Transfer and Immunogenicity
Branch, Office of Cellular, Tissue and
Gene Therapies, Center for Biologics
Evaluation and Research, FDA.
On page 63841, second column,
second paragraph, first sentence, the
Procedure portion is changed to read as
follows:
On November 29, 2012, from 1 p.m.
to 2:30 p.m. (Eastern Time) the meeting
is open to the public.
On page 63841, second column,
second paragraph, fourth sentence, the
Procedure portion is changed to read as
follows:
Oral presentations from the public
will be scheduled between
approximately 2:30 p.m. and 3:30 p.m.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden hours
per response
4
Total burden
hours
1.00
224
On page 63841, second column, third
paragraph, first sentence, the Closed
Committee Deliberations portion is
changed to read as follows:
On November 29, 2012 from
approximately 3:30 p.m. to 4:30 p.m.,
the meeting will be closed to permit
discussion where disclosure would
constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C.
552b(c)(6)).
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Dated: October 23, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2012–26635 Filed 10–29–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Notice of Intent To Make Changes in
the State Title V Maternal and Child
Health Block Grant Allocations
Health Resources and Services
Administration, HHS.
ACTION: Response to solicitation of
comments.
AGENCY:
The Health Resources and
Services Administration’s (HRSA)
Maternal and Child Health Bureau
(MCHB) plans to move forward in
implementing annual changes to the
State Title V MCH Block Grant
allocations, beginning in Federal Fiscal
Year (FY) 2013, using the U.S. Census
Bureau’s 3-year American Community
Survey (ACS) poverty estimates. Title V
MCH Block Grant funds are currently
allocated to states based in part on a
calculation of the number of children
living in poverty (in an individual state)
as compared to the total number of
children living in poverty in the United
States. Historically, data for the number
of children in poverty in each state
came from the Decennial Census. As the
Census Bureau has replaced the
Decennial Census long-form sample
questionnaire with the ACS, MCHB
SUMMARY:
E:\FR\FM\30OCN1.SGM
30OCN1
]]>Agencies
[Federal Register Volume 77, Number 210 (Tuesday, October 30, 2012)]
[Notices]
[Page 65693]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-26635]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0001]
Cellular, Tissue and Gene Therapies Advisory Committee; Amendment
of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of a meeting of the Cellular, Tissue and Gene Therapies
Advisory Committee. This meeting was announced in the Federal Register
of October 17, 2012 (77 FR 63840-63841). The amendment is being made to
reflect a change in the Date and Time, Agenda, Procedure, and Closed
Committee Deliberations portions of the document. There are no other
changes.
FOR FURTHER INFORMATION CONTACT: Gail Dapolito or Sheryl Clark, Center
for Biologics Evaluation and Research (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington DC area). Please call the Information Line for
up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of October 17,
2012, FDA announced that a meeting of the Cellular, Tissue and Gene
Therapies Advisory Committee would be held on November 29, 2012. On
page 63841, in the first column, the Date and Time portion of the
document is changed to read as follows:
The teleconference meeting will be held on November 29, 2012 from 1
p.m. to 4:30 p.m., Eastern Time.
On page 63841, in the first column, last paragraph, the Agenda
portion is changed to read as follows:
On November 29, 2012 the committee will meet in open session to
hear updates of research programs in the Gene Transfer and
Immunogenicity Branch, Office of Cellular, Tissue and Gene Therapies,
Center for Biologics Evaluation and Research, FDA.
On page 63841, second column, second paragraph, first sentence, the
Procedure portion is changed to read as follows:
On November 29, 2012, from 1 p.m. to 2:30 p.m. (Eastern Time) the
meeting is open to the public.
On page 63841, second column, second paragraph, fourth sentence,
the Procedure portion is changed to read as follows:
Oral presentations from the public will be scheduled between
approximately 2:30 p.m. and 3:30 p.m.
On page 63841, second column, third paragraph, first sentence, the
Closed Committee Deliberations portion is changed to read as follows:
On November 29, 2012 from approximately 3:30 p.m. to 4:30 p.m., the
meeting will be closed to permit discussion where disclosure would
constitute a clearly unwarranted invasion of personal privacy (5 U.S.C.
552b(c)(6)).
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: October 23, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-26635 Filed 10-29-12; 8:45 am]
BILLING CODE 4160-01-P
